Lercanidipino Aristo

Lercanidipine, the active ingredient in Lercanidipino Aristo, is a calcium channel blocker presented as an oral dosage form for systemic use. It is indicated for the treatment of hypertension in adult patients.

GNH USA supplies Lercanidipino Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine acts on the vascular smooth muscle to lower elevated blood pressure in patients with hypertension.

- Hypertension: reduces systolic and diastolic blood pressure, helping to achieve target levels. - Essential hypertension: improves long‑term cardiovascular risk management. - High blood pressure: provides sustained arterial vasodilation for better blood flow control.

Lercanidipine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, especially after the first dose. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: may occur with rapid posture changes. - Tachycardia: occasional increase in heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence, especially in patients with pre‑existing coronary disease. - Elevated liver enzymes: signs of hepatic stress, monitored via laboratory tests. - Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Before initiating therapy with Lercanidipine, several safety considerations should be observed.

- Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Hepatic impairment: use with caution; dose adjustment may be required. - Severe aortic stenosis: contraindicated due to risk of hypotension. - Elderly patients: start at the lowest effective dose and monitor closely. - Concomitant antihypertensives: assess for additive blood pressure‑lowering effects. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce therapeutic effect. - Grapefruit juice: can markedly raise drug levels. - Other potent vasodilators: risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, requiring dose adjustments. - Beta‑blockers: additive blood pressure reduction. - NSAIDs: may blunt antihypertensive response. - Digoxin: monitor for potential changes in serum levels.